Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron-chelating therapy.

C Hershko1, D J Weatherall

  • 1Department of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.

Critical Reviews in Clinical Laboratory Sciences
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Conclusions and recommendations of a WHO expert consultation meeting on iron supplementation for infants and young children in malaria endemic areas].

Medecine tropicale : revue du Corps de sante colonial·2008
Same author

Objectives and methods of iron chelation therapy.

Bioinorganic chemistry and applications·2008
Same author

[Lead poisoning by contaminated flour: an unfinished story].

Harefuah·2005
Same author

Treating iron overload: the state of the art.

Seminars in hematology·2005
Same author

Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.

European journal of haematology·2003
Same author

The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment.

The Journal of laboratory and clinical medicine·2002

Iron overload causes cellular damage, but iron-chelating drugs like deferoxamine may help. New oral iron chelators are needed for conditions like autoimmune disease and organ transplantation.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Iron's catalytic role in redox reactions generates harmful oxygen species, leading to cellular damage.
  • Iron overload has clinical manifestations that can be managed with iron-chelating drugs.
  • Deferoxamine (DF) is an iron-chelating drug used to treat iron overload.

Purpose of the Study:

  • To explore the potential of deferoxamine (DF) beyond iron overload treatment.
  • To investigate DF's role in mitigating free radical damage in inflammatory conditions.
  • To highlight the need for novel, orally effective iron chelators.

Main Methods:

  • Review of experimental evidence on deferoxamine's therapeutic potential.
  • Analysis of free radical formation in inflammatory responses.

Related Experiment Videos

  • Identification of new classes of orally effective iron chelators.

    • Main Results:

    • Deferoxamine (DF) may prevent free radical formation, impacting tissue damage in inflammation.
    • DF shows potential in managing autoimmune diseases, ARDS, and organ transplantation.
    • Existing oral iron chelators face challenges like poor absorption, high cost, and short action.

    Conclusions:

    • Deferoxamine (DF) exhibits therapeutic potential beyond iron overload by targeting free radicals.
    • Novel oral iron chelators, including polyanionic amines, aryl hydrazones, and hydroxypyridones, are promising.
    • Further research and development are crucial for clinical application of new iron-chelating drugs.